Drugs / Neflamapimod
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 29 trials · 3 met primary · 2 missed | ||||||
| Phase 2 | NCT07033481 | Oct 2025 → Sep 2026 overdue | progressive non-fluent aphasia | EIP Pharma Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06815965 | Oct 2024 → Mar 2026 | Lewy body dementia | EIP Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT05869669 | May 2023 → May 2025 | Lewy body dementia | EIP Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT04001517 | Sep 2019 → Jun 2020 | Lewy body dementia | EIP Pharma Inc | Completed | Met primary |
| Phase 2 | NCT03980938 | Jul 2019 → Oct 2020 | Huntington disease | EIP Pharma Inc | Terminated | No outcome recorded |
| Phase 2 | NCT03435861 | Oct 2018 → Apr 2021 | Alzheimer disease | University Hospital, Toulouse | Completed | Missed primary |
| Phase 2 | NCT03402659 | Dec 2017 → Jun 2019 | Alzheimer disease | EIP Pharma Inc | Completed | Missed primary |
| Phase 2 | NCT02423200 | Apr 2015 → Sep 2016 | Alzheimer disease | EIP Pharma Inc | Completed | Met primary |
| Phase 2 | NCT02423122 | Apr 2015 → Jul 2016 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | EIP Pharma Inc | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06987643 Comparator | Jun 2025 → Sep 2026 overdue | ischemic stroke | EIP Pharma Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2023-04-03 | CervoMed, Inc. | Results EIP Pharma Announces Presentation of Neuroimaging Data Exhibiting Potential Effects of Neflamapimod on Cholinergic Structure and Function at AD/PD™ 2023 cervomed.com ↗
The analysis demonstrated that the NbM volume was statistically significantly higher at the end of treatment (EOT, mean 3.1% higher vs. baseline, p=0.03); with 8 of 15 patients having greater than 3% higher NbM volume at EOT, compared to baseline. |
| 2023-01-18 | CervoMed, Inc. | Regulatory National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma’s neflamapimod in dementia with Lewy bodies cervomed.com ↗ |
| 2022-12-02 | CervoMed, Inc. | Results Presentation of MRI data at Clinical Trials and Alzheimer’s Disease (CTAD) conference demonstrates potential of neflamapimod to positively impact the cholinergic degenerative process in early Alzheimer’s disease (AD) cervomed.com ↗
In structural MRI images obtained before and after 12 weeks treatment, neflamapimod significantly increased the volume of the Nucleus Basalis of Meynert, the major nucleus of cholinergic neurons in the basal forebrain, in patients with early AD |
| 2022-09-21 | CervoMed, Inc. | Results EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications cervomed.com ↗
Phase 2a data in Dementia with Lewy Bodies show positive effects of neflamapimod on clinical endpoints associated with cholinergic neuronal function |
| 2021-11-10 | CervoMed, Inc. | Results Presentation at 14th CTAD Conference November 10, 2021 cervomed.com ↗
EIP Pharma announces that final results of the AscenD-LB phase 2 clinical study demonstrates neflamapimod has disease-modifying potential in dementia with Lewy Bodies |
| 2020-12-16 | CervoMed, Inc. | Results EIP Pharma Announces Publication of Preclinical Results Demonstrating Potential of Neflamapimod to Promote Functional Recovery after Ischemic Stroke cervomed.com ↗
The major findings showed that neflamapimod treatment, relative to vehicle treatment: Significantly improved, relative to vehicle treatment, behavioral outcomes assessed by the modified neurological severity score (mNSS) at Week 4 and at Week 6 post stroke in a dose-dependent manner (p<0.001). |
| 2020-11-07 | CervoMed, Inc. | Results EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer’s Disease (CTAD) Meeting cervomed.com ↗ |
| 2020-10-06 | CervoMed, Inc. | Results EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB) cervomed.com ↗ |
| 2019-12-05 | CervoMed, Inc. | Results EIP Pharma Announces Presentation of Phase 2b Clinical Trial Results of Neflamapimod in Early-stage Alzheimer’s Disease at Clinical Trials in Alzheimer’s Disease (CTAD) meeting cervomed.com ↗
The CSF biomarker effects of neflamapimod demonstrate (1) target engagement and (2) p38⍺ kinase inhibition impacts the AD disease process, that is, provides proof-of-mechanism,” concluded Professor Philip Scheltens of the VU Medical Center in Amsterdam, and the principal investigator of the study. |
| 2019-11-07 | CervoMed, Inc. | Regulatory EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB) cervomed.com ↗ |
| 2019-11-07 | CervoMed, Inc. | Results EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer’s Disease cervomed.com ↗ |
| 2019-07-17 | CervoMed, Inc. | Results EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38α Kinase Inhibitor Neflamapimod on the Neurodegenerative Process cervomed.com ↗
Neflamapimod reduced Amyloid-β derived diffusible ligand (ADDL)-induced dendritic spine retraction starting at the lowest concentration tested (10 nM) and fully blocked the effect at 50 nM. |
| 2018-03-07 | CervoMed, Inc. | Results EIP Pharma Announces Publication of Positive Alzheimer’s Disease Clinical Study Data with Neflamapimod cervomed.com ↗
Neflamapimod demonstrated a robust signal of efficacy on measures of episodic memory in this study, |
| 2017-07-19 | CervoMed, Inc. | Results EIP Pharma announces presentation of new mechanism of action data regarding neflamapimod (VX-745) at Alzheimer’s Association International Conference (AAIC) cervomed.com ↗
The results showed the known endosomal abnormalities in DS-fibroblasts, which serve as a human in-vitro system for AD pathophysiology (Jiang et al, PNAS, 2010), were reversed with 1, 10 or 50 nM neflamapimod. |
| 2017-07-18 | CervoMed, Inc. | Results EIP Pharma announces presentation of new positive clinical data with neflamapimod (VX-745) at Alzheimer’s Association International Conference (AAIC) cervomed.com ↗
The new analyses revealed consistent and substantial treatment effects on immediate and delayed recall aspects of episodic memory, as within-subject effect sizes (Cohen’s davg) were similar between the two studies and ranged between 0.59 and 0.86. |
| 2016-11-08 | CervoMed, Inc. | Results EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer’s Disease cervomed.com ↗
EIP Pharma, LLC (www.eippharma.com) today announced that it has obtained proof-of-mechanism for neflamapimod (previously code named VX-745), with the results of two recently completed Phase 2a clinical trials that demonstrated significant Alzheimer’s disease relevant pharmacological activity. |
| 2015-12-16 | CervoMed, Inc. | Results EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor cervomed.com ↗
EIP Pharma LLC today announced the publication in the Journal of Alzheimer’s Disease of an article entitled “Selective brain-targeted antagonism of p38 MAPK alpha reduces hippocampal IL-1 beta levels and improves Morris-Water-Maze Performance in Aged Rats,” which demonstrates pro-cognitive effects of VX-745 for the first time. |
All press releases naming this drug 24 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | neflamapimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06815965 ↗ |
| Known as | NEFLAMAPIMOD (VX-745) | ChEMBL registry synonym — accepted as the source's own label CHEMBL119385 ↗ |
| Known as | VD-31 | ChEMBL registry synonym — accepted as the source's own label CHEMBL119385 ↗ |
| Known as | VD-31,745 | ChEMBL registry synonym — accepted as the source's own label CHEMBL119385 ↗ |
| Known as | VRT-031745 | ChEMBL registry synonym — accepted as the source's own label CHEMBL119385 ↗ |
| Known as | VX-745 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03435861 ↗ |
| Action | Inhibit | “Orally-active P38 MAP kinase alpha-selective inhibitor” NCT02423200 ↗ |
| Modality | Small molecule | “oral small molecule selective inhibitor of p38 alpha kinase” NCT03402659 ↗ |
| Route | Oral | “12-Week Oral Twice-Daily Dosing” NCT02423122 ↗ |
| Target | MAPK14 | “Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase 14 (p38α).” NCT06815965 ↗ |